NCT00625950 is a Phase 4 clinical trial of ENDOMETRIAL BIOPSY in Hyperprolactinemia, sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA.

Who is sponsoring NCT00625950?

NCT00625950 is sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA.

What drugs are being tested in NCT00625950?

Interventions in NCT00625950: ENDOMETRIAL BIOPSY.

What condition does NCT00625950 study?

NCT00625950 studies Hyperprolactinemia, Endometriosis.

Is NCT00625950 still recruiting?

NCT00625950 is currently completed. Last updated 9 January 2009.

Last reviewed 2009-01-09 · How we verify

NCT00625950

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.

Completed Phase 4 Last updated 9 January 2009

What this trial tests

Phase 4 trial testing ENDOMETRIAL BIOPSY in Hyperprolactinemia in 5 participants. Completed in 1 May 2008.

Timeline

1 February 2008

Primary endpoint
1 April 2008

1 May 2008

Quick facts

Lead sponsor	Instituto Valenciano de Infertilidad, IVI VALENCIA
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	5
Start date	1 February 2008
Primary completion	1 April 2008
Estimated completion	1 May 2008
Sites	1 location across Spain

Drugs / interventions tested

ENDOMETRIAL BIOPSY

Conditions studied

Hyperprolactinemia — all drugs for Hyperprolactinemia →
Endometriosis — all drugs for Endometriosis →

Sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA — full company profile →

Who can join

Adults 18 to 37, female only, with Hyperprolactinemia or Endometriosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

observation of three month treatment with Quinagolida in endometriosis patients
Time frame: onset and three months after onset

Sponsor's own description

Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A call for more transparency of registered clinical trials on endometriosis.
Guo SW, Hummelshoj L, Olive DL, Bulun SE, et al · · 2009 · cited 32× · PMID 19264712 · DOI 10.1093/humrep/dep045
The Hallmarks of Endometriosis.
Psilopatis I, Burghaus S, Au K, Hofbeck L, et al · · 2024 · cited 6× · PMID 38884026 · DOI 10.1055/a-2306-8759
Dopamine D2 Receptor Agonists as Modulators of VEGF-A-Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities.
Akkanapally V, Kumar A, Ezhil I, Sahu MR, et al · · 2026 · PMID 42117522 · DOI 10.1096/fj.202600843r

Verify or expand the search:

Other recruiting trials for Hyperprolactinemia

Currently open trials in the same condition.

NCT07124221 — A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets · Phase 3 · recruiting
NCT07008417 — A Study on Bioequivalence of Cabergoline Tablets in Human Body · Phase 1 · active not recruiting

Other Instituto Valenciano de Infertilidad, IVI VALENCIA trials

Trials by the same sponsor.

NCT06193135 — Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitar · NA · recruiting
NCT06384794 — Study of the ZyMōt Sperm Selection Method and Its Effect on Embryo Ploidy. · NA · recruiting
NCT06103383 — Second Phase of the Pilot Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women · NA · unknown
NCT05440019 — Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration · completed
NCT05161338 — Impact of Vaginal Microbiome on Vaginal Absorption of Exogenous Progesterone: a Pilot Study. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00625950 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Valenciano de Infertilidad, IVI VALENCIA
Last refreshed: 9 January 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00625950.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing